US › Healthcare

Revvity Inc. (RVTY)

US · Healthcare · Diagnostics & Research

$111.39-3.32%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$711.1M

Revenue YoY

+7.0%

Net profit

$40.7M

Profit YoY

-3.6%

EPS

$1.06

EPS estimate

$1.01

Net margin

5.7%

EPS came in at 1.06 against a street estimate of 1.01 — a beat of 5.0%.

Key statistics

Market cap

$12.55B

P/E

54.1

Forward P/E

21.5

P/B

1.75

Book value

$64.34

EPS (TTM)

$2.08

Dividend yield

0.25%

52-week high

$118.13

52-week low

$81.14

50-day MA

$106.02

200-day MA

$98.92

Beta

1.09

Analyst view

Analysts rate Revvity Inc. a buy (12 buy, 7 hold, 0 sell out of 19) with an average price target of $117.13.

Shareholding

Insiders

0.35%

Institutions

107.02%

Largest institutional holders

Fund	Stake
T. Rowe Price Investment Management,Inc.	19.90%
T. Rowe Price Associates, Inc.	9.04%
EdgePoint Investment	7.89%
HHG PLC	7.48%
Vanguard Capital Management, LLC	6.57%
BlackRock Inc	6.50%
Vanguard Portfolio Management, LLC	4.31%
State Street Corp	3.86%

Recent filings & reports

Document	Date
Quarterly report · Q2 2026	2026-05-12
Results announced · Q2 2026	2026-05-05
Charter / bylaws change · Q2 2026	2026-05-01
Proxy statement · Q2 2026	2026-03-16
Annual report FY2025	2026-02-24
Results announced · Q1 2026	2026-02-02
Results announced · Q1 2026	2026-01-13
Quarterly report · Q3 2025	2025-11-04

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Revvity Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.